Unknown

Dataset Information

0

TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis?


ABSTRACT: The concept that increasing airway hydration leads to improvements in mucus clearance and lung function in cystic fibrosis has been clinically validated with osmotic agents such as hypertonic saline and more convincingly with cystic fibrosis transmembrane conductance regulator (CFTR) repair therapies. Although rapidly becoming the standard of care in cystic fibrosis (CF), current CFTR modulators do not treat all patients nor do they restore the rate of decline in lung function to normal levels. As such, novel approaches are still required to ensure all with CF have effective therapies. Although CFTR plays a fundamental role in the regulation of fluid secretion across the airway mucosa, there are other ion channels and transporters that represent viable targets for future therapeutics. In this review article we will summarise the current progress with CFTR-independent approaches to restoring mucosal hydration, including epithelial sodium channel (ENaC) blockade and modulators of SLC26A9. A particular emphasis is given to modulation of the airway epithelial calcium-activated chloride channel (CaCC), TMEM16A, as there is controversy regarding whether it should be positively or negatively modulated. This is discussed in light of a recent report describing for the first time bona fide TMEM16A potentiators and their positive effects upon epithelial fluid secretion and mucus clearance.

SUBMITTER: Danahay H 

PROVIDER: S-EPMC7177896 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis?

Danahay Henry H   Gosling Martin M  

International journal of molecular sciences 20200330 7


The concept that increasing airway hydration leads to improvements in mucus clearance and lung function in cystic fibrosis has been clinically validated with osmotic agents such as hypertonic saline and more convincingly with cystic fibrosis transmembrane conductance regulator (CFTR) repair therapies. Although rapidly becoming the standard of care in cystic fibrosis (CF), current CFTR modulators do not treat all patients nor do they restore the rate of decline in lung function to normal levels.  ...[more]

Similar Datasets

| S-EPMC7159426 | biostudies-literature
| S-EPMC7073096 | biostudies-literature
| S-EPMC5662572 | biostudies-literature
| S-EPMC3484098 | biostudies-literature
| S-EPMC3057187 | biostudies-literature
| S-EPMC8151571 | biostudies-literature
| S-EPMC4163837 | biostudies-literature
| S-EPMC8048771 | biostudies-literature
| S-EPMC6514296 | biostudies-literature
2011-01-07 | E-GEOD-26482 | biostudies-arrayexpress